Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease therapies, has scheduled its fourth quarter 2024 financial results announcement for Monday, March 10, 2025. The results will be released before U.S. financial markets open.
Aligos Therapeutics (Nasdaq: ALGS), un'azienda biotech in fase clinica specializzata in terapie per malattie epatiche e virali, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre 2024 per lunedì 10 marzo 2025. I risultati saranno resi noti prima dell'apertura dei mercati finanziari statunitensi.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biotecnológica en etapa clínica especializada en terapias para enfermedades hepáticas y virales, ha programado el anuncio de sus resultados financieros del cuarto trimestre de 2024 para el lunes 10 de marzo de 2025. Los resultados se publicarán antes de la apertura de los mercados financieros en EE. UU.
알리고스 테라퓨틱스 (Nasdaq: ALGS), 간 및 바이러스 질환 치료에 전문화된 임상 단계 생명공학 회사가 2024년 4분기 재무 결과 발표를 2025년 3월 10일 월요일로 예정했습니다. 결과는 미국 금융 시장이 개장하기 전에 발표될 예정입니다.
Aligos Therapeutics (Nasdaq: ALGS), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies pour les maladies hépatiques et virales, a prévu d'annoncer ses résultats financiers du quatrième trimestre 2024 pour le lundi 10 mars 2025. Les résultats seront publiés avant l'ouverture des marchés financiers américains.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Leber- und Viruskrankheiten spezialisiert hat, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal 2024 für Montag, den 10. März 2025 angesetzt. Die Ergebnisse werden vor der Eröffnung der US-Finanzmärkte veröffentlicht.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics (ALGS) release Q4 2024 earnings?
What is the timing of ALGS Q4 2024 financial results announcement?
What market segment does Aligos Therapeutics (ALGS) operate in?
Which stock exchange is ALGS listed on?
